Market Place
Sourcing Support
Mydecine Receives Two Notice of Allowances from USPTO for MYCO-005 and MYCO-006
07 Feb 2024 //
GLOBENEWSWIRE
Mydecine Announces Update Regarding the Special Access Program
28 Nov 2023 //
GLOBENEWSWIRE
Mydecine Innovations Announces Closing Under Share Subscription Agreements
31 Oct 2023 //
GLOBENEWSWIRE
Mydecine Provides Q4 2023 Business Update
26 Oct 2023 //
GLOBENEWSWIRE
Mydecine Announces Admission to Trading on the AQSE Growth Market in London, UK
12 Oct 2023 //
GLOBENEWSWIRE
Mydecine Innovations Group Announces Admission to Trading on the AQSE
10 Oct 2023 //
GLOBENEWSWIRE
MydecineAnnounces Listing on the Canadian Securities Exchange
05 Oct 2023 //
GLOBENEWSWIRE
Mydecine Innovations Group Announces Expected U.K. Dual Listing Admission Date
27 Sep 2023 //
GLOBENEWSWIRE
Mydecine Innovations Announces Closing of Prospectus Supplement Financing
19 Sep 2023 //
GLOBENEWSWIRE
Mydecine Innovations Group Files Prospectus Supplement
15 Sep 2023 //
GLOBENEWSWIRE
Mydecine Reports Financial Results for the Second Quarter of Fiscal Year 2023
14 Aug 2023 //
GLOBENEWSWIRE
Mydecine Innovations Group Provides Corporate Update
21 Jul 2023 //
GLOBENEWSWIRE
Mydecine Reports its Special Meeting Results
05 Jul 2023 //
GLOBENEWSWIRE
Mydecine Reports Financial Results for the First Quarter of Fiscal Year 2023
16 May 2023 //
GLOBENEWSWIRE
Mydecine Reports Positive Results on MYCO-006 Series of its MDMA Analogues
24 Apr 2023 //
GLOBENEWSWIRE
Mydecine Innovations Group Provides Corporate Update
03 Apr 2023 //
GLOBENEWSWIRE
Mydecine Reports Financial Results for the Year Ended December 2022
31 Mar 2023 //
GLOBENEWSWIRE
Mydecine Announces Debt Settlements
06 Mar 2023 //
GLOBENEWSWIRE
Mydecine Innovations Group Closes Sale of Its Wholly-Owned Subsidiary, Mindleap
12 Dec 2022 //
GLOBENEWSWIRE
Mydecine Innovations Group Files Prospectus Supplement
21 Nov 2022 //
GLOBENEWSWIRE
Mydecine Innovations Group Announces Common Share Subscription Agreement
29 Aug 2022 //
GLOBENEWSWIRE
Mydecine Innovations Group Announces Private Placement
19 Aug 2022 //
GLOBENEWSWIRE
Mydecine Reports Financial Results for the Second Quarter of Fiscal Year 2022
15 Aug 2022 //
GLOBENEWSWIRE
Mydecine Files Full Patent Application Covering MYCO-006 Family
19 Jul 2022 //
GLOBENEWSWIRE
FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation
17 Jun 2022 //
GLOBENEWSWIRE
Mydecine Provides Company Update; Welcomes New Board Member
09 Jun 2022 //
GLOBENEWSWIRE
Mydecine Announces First Quarter 2022 Financial Results and Highlights
16 May 2022 //
GLOBENEWSWIRE
Mydecine Reports Financial Results for the Fiscal Year 2021
31 Mar 2022 //
GLOBENEWSWIRE
Mydecine Receives Conditional IRB Approval for Phase 2b Smoking Cessation Study
24 Mar 2022 //
GLOBENEWSWIRE
Mydecine To Attend March Investor Conferences
03 Mar 2022 //
GLOBENEWSWIRE
Mydecine Reports Positive Pre-IND Meeting With FDA For MYCO-001 Study
01 Mar 2022 //
GLOBENEWSWIRE
Mydecine Announces MYCO-005 Family of Improved Safety Microdose Novel Molecules
16 Feb 2022 //
GLOBENEWSWIRE
Mydecine Submits Pre-IND to FDA for MYCO-001 Phase 2/3 Smoking Cessation Trial
01 Feb 2022 //
GLOBENEWSWIRE
Mydecine Partners with Combat Stress to Treat PTSD in Veterans
24 Jan 2022 //
GLOBENEWSWIRE
Mydecine Signs LOI with The Newly Institute for Psychedelic-Aided Psychotherapy
18 Jan 2022 //
GLOBENEWSWIRE
Mydecine to Launch Special Access Support and Supply Program in Canada
13 Jan 2022 //
GLOBENEWSWIRE
Mydecine Achieves Innovative Supercomputing AI Modeling in Psychedelics
10 Jan 2022 //
GLOBENEWSWIRE
Mydecine Innovations Group Engages JBN Partners, LLC for Marketing Services
07 Jan 2022 //
GLOBENEWSWIRE
Mydecine Signs LOI with Maya to Co-Develop a Novel Prescription Digital Platform
22 Dec 2021 //
GLOBENEWSWIRE
Mydecine Secures Financing and Provides Company Update on Clinical Trials
09 Dec 2021 //
GLOBENEWSWIRE
Mydecine Files Full Patent Application Covering New Formulations
03 Nov 2021 //
GLOBENEWSWIRE
Mydecine Innovations Group Receives Shareholder and Court Approval for Spin-Out
24 Sep 2021 //
BUSINESSWIRE
Mydecine Files MYCO-003 Final Patent Application and Reports Preclinical Data
22 Sep 2021 //
GLOBENEWSWIRE
Mydecine to initiate ph2/3 trial of psilocybin for smoking cessation
07 Sep 2021 //
SEEKINGALPHA
Mydecine Announces Mailing of Information Circular; Cannabis spin-out update
24 Aug 2021 //
GLOBENEWSWIRE
Mydecine Innovations signs five-year Master Collaboration Research Agreement
18 Aug 2021 //
GLOBENEWSWIRE
Mydecine Reports Second Quarter 2021 Financial Results
16 Aug 2021 //
GLOBENEWSWIRE
Mydecine Expands Portfolio Novel Molecules Filing New Patent MDMALike Compound
21 Jul 2021 //
GLOBENEWSWIRE
Mydecine Innovations Group Announces Launch of Mindleap Version 2.0
13 Jul 2021 //
GLOBENEWSWIRE
Mydecine Selects Substance Use Disorder & Smoking Cessation for MYCO-004
24 Jun 2021 //
GLOBENEWSWIRE
Mydecine to Participate in the ROTH Virtual Healthcare Private Company Forum
23 Jun 2021 //
GLOBENEWSWIRE
Mydecine Unveils Artificial Intelligence Drug Discovery Program
16 Jun 2021 //
GLOBENEWSWIRE
Mydecine Discovers 40 Pharmacologically Active Novel Compounds in Mushrooms
09 Jun 2021 //
GLOBENEWSWIRE
Mydecine Announces API-naming structure of Four Candidates Pre-IND
07 Apr 2021 //
GLOBENEWSWIRE
Mydecine Innovations Group Provides Update on European Operations
15 Mar 2021 //
BIOSPACE
Mydecine Innovations Group Sponsors Study on Neuron Level Response
28 Jan 2021 //
GLOBENEWSWIRE
Mydecine Innovations Group Files Preliminary Prospectus in Connection
22 Jan 2021 //
BUSINESSWIRE
Mydecine Innovations Files Preliminary Prospectus Connection with Bought Deal
21 Jan 2021 //
BUSINESSWIRE
Mydecine Innovations Group Inc. Announces NeuroPharm Inc. Commences PTSD
16 Jul 2020 //
PRNEWSWIRE
Mydecine Innovations Group Signs Definitive Agreement Acquisition of NeuroPharm
14 Jul 2020 //
PRNEWSWIRE
